Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Saylor

Showing results (51-60 of 82) with videos related to

Pageof 9
Sort By:
Oncotarget|April 15, 2016
Whole exome sequencing of urachal adenocarcinoma reveals recurrent NF1 mutationsHarshabad Singh, Yang Liu, Xiuli Xiao, et al.
European Journal of Nuclear Medicine and Molecular Imaging|September 8, 2019
Performance of <sup>18</sup>F-fluciclovine PET/MR in the evaluation of osseous metastases from castration-resistant prostate cancerBarbara J Amorim, Vinay Prabhu, Sara S Marco, et al.
Journal of Neurosurgery. Spine|June 25, 2021
The effectiveness of systemic therapies after surgery for metastatic renal cell carcinoma to the spine: a propensity analysis controlling for sarcopenia, frailty, and nutritionElie Massaad, Philip J Saylor, Muhamed Hadzipasic, et al.
Abdominal Radiology (New York)|September 20, 2025
Prognostic value of MRI-derived features for biochemical recurrence after curative radiotherapy in prostate cancerAlexander Herold, Maximilian Pohl, Stephan M Korn, et al.
The Oncologist|February 4, 2012
Changes in biomarkers of inflammation and angiogenesis during androgen deprivation therapy for prostate cancerPhilip J Saylor, Kevin R Kozak, Matthew R Smith, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 29, 2020
Bone Health and Bone-Targeted Therapies for Prostate Cancer: ASCO Endorsement of a Cancer Care Ontario GuidelinePhilip J Saylor, R Bryan Rumble, Scott Tagawa, et al.
Journal of the American Society of Echocardiography : Official Publication of the American Society of Echocardiography|March 18, 2024
Cardiac Structural Changes and Declining Cardiorespiratory Fitness During Androgen Deprivation Therapy for Prostate CancerTimothy W Churchill, Matthew R Smith, M Dror Michaelson, et al.
Molecular Cancer Research : MCR|March 19, 2025
Single-cell and spatial transcriptomics reveal a tumor-associated macrophage subpopulation that mediates prostate cancer progression and metastasisShenglin Mei, Hanyu Zhang, Taghreed Hirz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 22, 2016
Branched Chain RNA In Situ Hybridization for Androgen Receptor Splice Variant AR-V7 as a Prognostic Biomarker for Metastatic Castration-Sensitive Prostate CancerPhilip J Saylor, Richard J Lee, Kshitij S Arora, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|January 15, 2024
The radiopharmaceutical radium-223 has immunomodulatory effects in patients and facilitates anti-programmed death receptor-1 therapy in murine models of bone metastatic prostate cancerPhilip J Saylor, Sergey V Kozin, Aya Matsui, et al.
Pageof 9

Showing results (51-60 of 82) with videos related to

Sort By:
Pageof 9
Oncotarget|April 15, 2016
Whole exome sequencing of urachal adenocarcinoma reveals recurrent NF1 mutationsHarshabad Singh, Yang Liu, Xiuli Xiao, et al.
European Journal of Nuclear Medicine and Molecular Imaging|September 8, 2019
Performance of <sup>18</sup>F-fluciclovine PET/MR in the evaluation of osseous metastases from castration-resistant prostate cancerBarbara J Amorim, Vinay Prabhu, Sara S Marco, et al.
Journal of Neurosurgery. Spine|June 25, 2021
The effectiveness of systemic therapies after surgery for metastatic renal cell carcinoma to the spine: a propensity analysis controlling for sarcopenia, frailty, and nutritionElie Massaad, Philip J Saylor, Muhamed Hadzipasic, et al.
Abdominal Radiology (New York)|September 20, 2025
Prognostic value of MRI-derived features for biochemical recurrence after curative radiotherapy in prostate cancerAlexander Herold, Maximilian Pohl, Stephan M Korn, et al.
The Oncologist|February 4, 2012
Changes in biomarkers of inflammation and angiogenesis during androgen deprivation therapy for prostate cancerPhilip J Saylor, Kevin R Kozak, Matthew R Smith, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 29, 2020
Bone Health and Bone-Targeted Therapies for Prostate Cancer: ASCO Endorsement of a Cancer Care Ontario GuidelinePhilip J Saylor, R Bryan Rumble, Scott Tagawa, et al.
Journal of the American Society of Echocardiography : Official Publication of the American Society of Echocardiography|March 18, 2024
Cardiac Structural Changes and Declining Cardiorespiratory Fitness During Androgen Deprivation Therapy for Prostate CancerTimothy W Churchill, Matthew R Smith, M Dror Michaelson, et al.
Molecular Cancer Research : MCR|March 19, 2025
Single-cell and spatial transcriptomics reveal a tumor-associated macrophage subpopulation that mediates prostate cancer progression and metastasisShenglin Mei, Hanyu Zhang, Taghreed Hirz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 22, 2016
Branched Chain RNA In Situ Hybridization for Androgen Receptor Splice Variant AR-V7 as a Prognostic Biomarker for Metastatic Castration-Sensitive Prostate CancerPhilip J Saylor, Richard J Lee, Kshitij S Arora, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|January 15, 2024
The radiopharmaceutical radium-223 has immunomodulatory effects in patients and facilitates anti-programmed death receptor-1 therapy in murine models of bone metastatic prostate cancerPhilip J Saylor, Sergey V Kozin, Aya Matsui, et al.
Pageof 9